Cwm LLC Cuts Holdings in Humana Inc. $HUM

Cwm LLC decreased its holdings in Humana Inc. (NYSE:HUM) by 50.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,465 shares of the insurance provider’s stock after selling 10,454 shares during the period. Cwm LLC’s holdings in Humana were worth $2,558,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in shares of Humana in the 1st quarter valued at about $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Humana by 16.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after acquiring an additional 158,528 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Humana by 104.2% in the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after acquiring an additional 3,281 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock valued at $33,256,000 after acquiring an additional 2,950 shares during the last quarter. Finally, Circle Wealth Management LLC bought a new position in shares of Humana in the 1st quarter valued at about $425,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Humana stock opened at $275.00 on Friday. The company has a 50 day moving average price of $280.54 and a 200-day moving average price of $258.18. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The company has a market capitalization of $33.07 billion, a PE ratio of 21.11, a P/E/G ratio of 1.61 and a beta of 0.42.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the firm posted $6.96 EPS. The business’s revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is currently 27.17%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUM. The Goldman Sachs Group initiated coverage on shares of Humana in a report on Tuesday. They issued a “sell” rating and a $235.00 price target for the company. Sanford C. Bernstein raised their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Barclays decreased their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. Robert W. Baird decreased their price objective on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. Finally, Wall Street Zen downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.